Although it is not surprising that the Src and c-Abl inhibitor saracatinib has anti-proliferative effects on RASF, the increased uptake in inflammatory conditions makes saracatinib a promising therapeutic option for RA. The gene discussed is ABL1; the disease is rheumatoid arthritis.